These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22238924)

  • 1. [Breast cancer subtypes and their endocrine-metabolic basis; practical aspects].
    Bershteĭn LM; Semiglazov VF
    Vopr Onkol; 2011; 57(5):559-66. PubMed ID: 22238924
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endocrine therapy for postmenopausal breast cancer (role of cycline D1)].
    Manikhas AG; Skvortsov VA; Manikhas GM; Raskin GA; Oganesian AS; Shemerovskiĭ AK
    Vopr Onkol; 2011; 57(5):641-4. PubMed ID: 22238936
    [No Abstract]   [Full Text] [Related]  

  • 3. [Strategies of breast cancer treatment based on determination of biological subtype].
    Semiglazov VF
    Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Brown RJ; Davidson NE
    Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
    Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
    [No Abstract]   [Full Text] [Related]  

  • 6. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
    Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
    Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
    Atkins CD
    J Natl Cancer Inst; 1998 Mar; 90(6):468-9. PubMed ID: 9521174
    [No Abstract]   [Full Text] [Related]  

  • 9. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is low-dose tamoxifen an effective therapy for breast carcinoma in situ?].
    Ivanova OA; Zhil'tsova EK; Barash NIu; Ivanov VG; Ermachenkova AM
    Vopr Onkol; 2011; 57(5):601-3. PubMed ID: 22238929
    [No Abstract]   [Full Text] [Related]  

  • 12. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing concepts of hormone receptor-positive advanced breast cancer therapy.
    Chlebowski RT
    Clin Breast Cancer; 2013 Jun; 13(3):159-66. PubMed ID: 23228361
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G; Mokbel K
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic targeting in breast cancer].
    Penault-Llorca F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
    [No Abstract]   [Full Text] [Related]  

  • 16. The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients.
    Bièche I; Parfait B; Noguès C; Andrieu C; Vidaud D; Spyratos F; Lidereau R; Vidaud M
    Oncogene; 2001 Oct; 20(47):6955-9. PubMed ID: 11687975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Sgroi DC; Haber DA; Ryan PD; Ma XJ; Erlander MG
    Cancer Cell; 2004 Nov; 6(5):445. PubMed ID: 15542428
    [No Abstract]   [Full Text] [Related]  

  • 18. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Ferretti G; Di Cosimo S; Giannarelli D; Carlini P; Papaldo P; Alimonti A; Fabi A; Mandalà M; Milella M; Ruggeri EM; Cognetti F
    J Clin Oncol; 2004 Feb; 22(3):568-9. PubMed ID: 14752083
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer.
    Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
    Oncol Rep; 2003; 10(1):141-4. PubMed ID: 12469160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tamoxifen: modern drug therapy of estrogen-dependent breast tumors].
    Jovanović-Mićić D; Beleslin DB; Nikolić SS
    Med Pregl; 1996; 49(7-8):287-90. PubMed ID: 8926945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.